ORG-201745: Difference between revisions
Appearance
Content deleted Content added
Identifier. |
|||
(2 intermediate revisions by 2 users not shown) | |||
Line 1: | Line 1: | ||
{{short description|Chemical compound}} |
|||
{{Drugbox |
{{Drugbox |
||
| Verifiedfields = |
| Verifiedfields = |
||
Line 35: | Line 36: | ||
| ATC_supplemental = |
| ATC_supplemental = |
||
| PubChem = |
| PubChem = |
||
| PubChemSubstance = 472220258 |
|||
| IUPHAR_ligand = |
| IUPHAR_ligand = |
||
| DrugBank_Ref = |
| DrugBank_Ref = |
||
Line 56: | Line 58: | ||
}} |
}} |
||
'''ORG-201745''' is a [[progestin]] which was originated by [[Organon]] and was under development by [[Schering-Plough]] (which acquired Organon in 2007) for the treatment of "[[female genital disease]]s" and as a [[hormonal contraceptive]] for the prevention of [[pregnancy]] but was never marketed.<ref name="AdisInsight">https://adisinsight.springer.com/drugs/800027574</ref> |
'''ORG-201745''' is a [[progestin]] which was originated by [[Organon]] and was under development by [[Schering-Plough]] (which acquired Organon in 2007) for the treatment of "[[female genital disease]]s" and as a [[hormonal contraceptive]] for the prevention of [[pregnancy]] but was never marketed.<ref name="AdisInsight">{{cite web |url=https://adisinsight.springer.com/drugs/800027574 | title=ORG 201745 - AdisInsight |website=adisinsight.springer.com}}</ref> |
||
==References== |
==References== |
||
{{Reflist}} |
{{Reflist}} |
||
==External links== |
|||
* [https://adisinsight.springer.com/drugs/800027574 ORG-201745 - AdisInsight] |
|||
{{Progesterone receptor modulators}} |
{{Progesterone receptor modulators}} |
Latest revision as of 01:12, 2 November 2024
Clinical data | |
---|---|
Drug class | Progestin; Progestogen |
Identifiers | |
CAS Number | |
PubChem SID |
ORG-201745 is a progestin which was originated by Organon and was under development by Schering-Plough (which acquired Organon in 2007) for the treatment of "female genital diseases" and as a hormonal contraceptive for the prevention of pregnancy but was never marketed.[1]
References
[edit]- ^ "ORG 201745 - AdisInsight". adisinsight.springer.com.